Janus kinase inhibitors
Janus kinase inhibitors
Overview
Janus kinase inhibitors (JAK inhibitors, or JAKis) are a class of targeted anti-inflammatory and immunomodulatory therapies that block signaling through the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway. The Janus kinase family comprises four members — JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) — which associate with cytokine receptors and phosphorylate STAT transcription factors; individual inhibitors differ in which of these kinases they preferentially block, and that selectivity shapes both their efficacy and their adverse-effect profiles. By suppressing JAK-mediated cytokine signaling, these agents reduce immune activation across a range of inflammatory, autoimmune, and myeloproliferative diseases, including rheumatoid arthritis, atopic dermatitis, alopecia areata, systemic sclerosis, scleritis, drug reaction with eosinophilia and systemic symptoms (DRESS), and myelofibrosis.
Agents in this class include the pan-JAK inhibitor tofacitinib, the JAK1/2 inhibitors baricitinib and ruxolitinib (the latter a mainstay of myelofibrosis therapy), and the more JAK1-selective agents upadacitinib and abrocitinib. Despite differing in selectivity and approved indications, they share the same core principle of suppressing cytokine-driven inflammation. Because JAK signaling is broadly involved in immune and hematopoietic pathways, the class carries a regulatory boxed warning for serious adverse events — including major adverse cardiovascular events, venous thromboembolism, malignancy, and serious infection — so the balance of efficacy, safety, and patient-reported outcomes remains a central focus of ongoing research.
Focus of Latest Publications
Recent publications on Janus kinase inhibitors have focused heavily on real-world effectiveness, safety, and treatment optimization across multiple immune-mediated diseases. In rheumatoid arthritis, one study set out to compare sarilumab with Janus kinase inhibitors in late-onset and younger-onset disease, reflecting ongoing interest in glucocorticoid- and methotrexate-sparing strategies. In systemic sclerosis, a multicenter real-life study evaluated longitudinal changes in pulmonary, articular, and cutaneous parameters among patients treated with Janus kinase inhibitors, underscoring their emerging use across multiple clinical domains.
Several recent studies examined Janus kinase inhibitors in dermatologic disease. In alopecia areata, a retrospective cohort study of patients treated with tofacitinib or ritlecitinib found better week-24 outcomes in acute versus non-acute disease, with acute cases more often achieving SALT100 and tofacitinib identified as a predictor of super-responder status. Another publication used a discrete choice experiment to assess patient preferences for treatment characteristics of Janus kinase inhibitors in alopecia areata, while a multinational cohort study in skin immune-mediated inflammatory diseases compared Janus kinase inhibitors with conventional immunomodulators and found no increase in mortality, major adverse cardiovascular events, venous thromboembolism, or malignancy over 2 years.
In inflammatory bowel disease, a multicenter retrospective cohort study in ulcerative colitis evaluated whether concomitant 5-aminosalicylic acid, including mesalazine, affected outcomes during treatment with tofacitinib, upadacitinib, or filgotinib. Clinical remission at week 48 was similar with and without 5-ASA, and the adjusted analysis found no significant effect on time to remission. Another retrospective study addressed flare characteristics in atopic dermatitis patients receiving Janus kinase inhibitors, highlighting that real-world flare incidence, presentation, predictors, and management remain insufficiently characterized outside randomized trials.
Other recent publications extended Janus kinase inhibitor research into hematologic malignancy and severe inflammatory syndromes. A Japanese real-world study in myelofibrosis described treatment patterns and outcomes in patients receiving ruxolitinib, the only Janus kinase inhibitor used in that cohort, with detailed reporting of anemia, thrombocytopenia, transfusion burden, and survival. In refractory drug reaction with eosinophilia and systemic symptoms, a small case series reported rapid clinical improvement and successful corticosteroid tapering with baricitinib or abrocitinib, alongside reductions in cytokines such as interleukin-5. Janus kinase inhibition has also been discussed in the context of severe immune-related adverse events from checkpoint inhibitor therapy, where a rapid response highlighted reported remission activity and the need to better define safety and the balance between irAE control and antitumor immunity.